Information for "Bevacizumab additionally erlotinib versus erlotinib on your own in Japanese people together with innovative metastatic EGFRmutant nonsmallcell united states NEJ026 overall tactical investigation of your openlabel randomised multicentre stage 3 trial"
From EECH Central
Basic information
| Display title | Bevacizumab additionally erlotinib versus erlotinib on your own in Japanese people together with innovative metastatic EGFRmutant nonsmallcell united states NEJ026 overall tactical investigation of your openlabel randomised multicentre stage 3 trial |
| Default sort key | Bevacizumab additionally erlotinib versus erlotinib on your own in Japanese people together with innovative metastatic EGFRmutant nonsmallcell united states NEJ026 overall tactical investigation of your openlabel randomised multicentre stage 3 trial |
| Page length (in bytes) | 3,632 |
| Page ID | 1290902 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Poisonsubway76 (Talk | contribs) |
| Date of page creation | 10:08, 22 March 2024 |
| Latest editor | Poisonsubway76 (Talk | contribs) |
| Date of latest edit | 10:08, 22 March 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 1 |
| Recent number of distinct authors | 1 |
